China-based 3SBio Inc. (HKG: 1530) reported its H1 2020 financial results, with revenue of RMB 3.091 billion (USD 451.5 million), a 0.51% decrease year-on-year (YOY). Net profits rose 6.19% YOY to RMB 955 million (USD 145.3 million). R&D investment increased 14.7% to RMB 294 million (USD 42.9 million).
Core Products
3SBio’s key products include TPIAO (recombinant thrombopoietin), which holds a 66.0% share of China’s thrombocytopenia treatment market, and Yisaipu (etanercept), a recombinant erythropoietin and antibody fusion protein drug. The company’s Contract Development and Manufacturing Organization (CDMO) business, launched in December 2019, also contributed to revenue.
Strategic Partnerships
In June 2020, 3SBio licensed its PD-1 monoclonal antibody 609A to US firm Syncromune for global development as a tumor immunotherapy combination. The same month, it granted Chengdu Kelingyuan Pharmaceutical Co., Ltd global rights to its anti-HER2 mAb Cipterbin (inetetamab) for development as an ADC component.
Product Pipeline
3SBio’s pipeline includes 33 drug candidates: 18 antibodies, 7 biologics, and 8 small molecules. These target cancer, autoimmune diseases, kidney diseases, skin diseases, and more, with a focus on rheumatoid arthritis, intractable gout, and age-related macular degeneration (AMD).-Fineline Info & Tech
